Academic article

• Dhanasekaran Sivakumaran; Synne Jenum; Dagfinn Lunde Markussen et al. (2024). Protein and transcriptional biomarker profiling may inform treatment strategies in lower respiratory tract infections by indicating bacterial–viral differentiation. (external link)
• Dagfinn Lunde Markussen; Jannicke Slettli Wathne; Christian Ritz et al. (2024). Determinants of non-adherence to antibiotic treatment guidelines in hospitalized adults with suspected community-acquired pneumonia: a prospective study. (external link)
• Dagfinn Lunde Markussen; Marit Helen Ebbesen; Sondre Serigstad et al. (2023). The diagnostic utility of microscopic quality assessment of sputum samples in the era of rapid syndromic PCR testing. (external link)
• Noelia Alonso Rodriguez; Eleonora Vianello; Suzanne van Veen et al. (2024). Whole blood RNA signatures in tuberculosis patients receiving H56:IC31 vaccine as adjunctive therapy. (external link)
• Dhanasekaran Sivakumaran; Synne Jenum; Aashish Srivastava et al. (2023). Host blood-based biosignatures for subclinical TB and incipient TB: A prospective study of adult TB household contacts in Southern India. (external link)
• Kristin Grotle Nore; Claire Louet; Marit Bugge et al. (2023). The Cyclooxygenase 2 Inhibitor Etoricoxib as Adjunctive Therapy in Tuberculosis Impairs Macrophage Control of Mycobacterial Growth. (external link)
• William Ward Siljan; Dhanasekaran Sivakumaran; Christian Ritz et al. (2022). Host Transcriptional Signatures Predict Etiology in Community-Acquired Pneumonia: Potential Antibiotic Stewardship Tools. (external link)
• Dhanasekaran Sivakumaran; Synne Jenum; Christian Ritz et al. (2022). Improving Assignments for Therapeutic and Prophylactic Treatment Within TB Households. A Potential for Immuno-Diagnosis?. (external link)
• Christina Skår Saghaug; Dagfinn Lunde Markussen; Siri Tandberg Knoop et al. (2025). Diagnostic accuracy of a host response test in suspected community-Acquired pneumonia during the COVID-19 era. (external link)
• Dhanasekaran Sivakumaran; Christian Ritz; John Espen Gjøen et al. (2021). Host blood RNA transcript and protein signatures for sputum-independent diagnostics of tuberculosis in adults. (external link)
• Thor Ueland; Lars Heggelund; Andreas Lind et al. (2020). Elevated plasma sTIM-3 levels in patients with severe COVID-19. (external link)
• Marthe Jøntvedt Jørgensen; Kristin Grotle Nore; Hans Christian Dalsbotten Aass et al. (2021). Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients. (external link)
• Synne Jenum; Rasmus Bakken; Dhanasekaran Sivakumaran et al. (2016). BLR1 and FCGR1A transcripts in peripheral blood associate with the extent of intrathoracic tuberculosis in children and predict treatment outcome. (external link)
• Jason Bouziotis; Marianna Arvanitakis; Jean-Charles Preiser et al. (2022). Association of body mass index with COVID-19 related in-hospital death. (external link)
• Synne Jenum; Dhanasekaran Sivakumaran; Rakesh Lodha et al. (2016). Approaching a diagnostic point-of-care test for pediatric tuberculosis through evaluation of immune biomarkers across the clinical disease spectrum. (external link)
• Bih Hycenta Chendi; Candice I. Snyders; Kristian Tonby et al. (2021). A Plasma 5-Marker Host Biosignature Identifies Tuberculosis in High and Low Endemic Countries. (external link)
• Bih Hycenta Chendi; Hallgeir Tveiten; Candice I. Snyders et al. (2021). CCL1 and IL-2Ra differentiate Tuberculosis disease from latent infection Irrespective of HIV infection in low TB burden countries. (external link)
• Munib Mesinovic; Xin Ci Wong; Giri Shan Rajahram et al. (2024). At-admission prediction of mortality and pulmonary embolism in an international cohort of hospitalised patients with COVID-19 using statistical and machine learning methods. (external link)
• Synne Jenum; Dhanasekaran Sivakumaran; Christian Ritz et al. (2016). Added Value of IP-10 as a Read-Out of Mycobacterium tuberculosis - Specific Immunity in Young Children.. (external link)
• Dhanasekaran Sivakumaran; Synne Jenum; Ruth Stavrum et al. (2014). Concordant or discordant results by the tuberculin skin test and the quantiFERON-TB test in children reflect immune biomarker profiles. (external link)
• Jan Cato Holter; Soeren Pischke; Eline de Boer et al. (2020). Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. (external link)
• Dhanasekaran Sivakumaran; Synne Jenum; Mario Vaz et al. (2020). Combining host-derived biomarkers with patient characteristics improves signature performance in predicting tuberculosis treatment outcomes. (external link)
• Hans-Kittil Viermyr; Bente Halvorsen; Ellen Lund Sagen et al. (2024). High viral loads combined with inflammatory markers predict disease severity in hospitalized COVID-19 patients: Results from the NOR-Solidarity trial. (external link)
• Sheryl Ann Abdukahil; Ryuzo Abe; Laurent Abel et al. (2021). COVID‐19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study. (external link)
• Marthe Jøntvedt Jørgensen; Jan Cato Holter; Erik Christensen et al. (2020). Increased interleukin-6 and macrophage chemoattractant protein-1 are associated with respiratory failure in COVID-19. (external link)
• Synne Jenum; Selvam Sumithra; Jesuraj Nelson et al. (2018). Incidence of tuberculosis and the influence of surveillance strategy on tuberculosis case-finding and all-cause mortality: A cluster randomised trial in Indian neonates vaccinated with BCG. (external link)
• John Espen Gjøen; Synne Jenum; Dhanasekaran Sivakumaran et al. (2017). Novel transcriptional signatures for sputum-independent diagnostics of tuberculosis in children. (external link)
• Bronner P. Gonçalves; Matthew Hall; Waasila Jassat et al. (2022). An international observational study to assess the impact of the Omicron variant emergence on the clinical epidemiology of COVID-19 in hospitalised patients. (external link)
• Luis Felipe Reyes; Srinivas Murthy; Esteban Garcia-Gallo et al. (2022). Respiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a prospective, multinational, observational study. (external link)
• Dhanasekaran Sivakumaran; Gretta Blatner; Rasmus Bakken et al. (2021). A 2-Dose AERAS-402 Regimen Boosts CD8⁺ Polyfunctionality in HIV-Negative, BCG-Vaccinated Recipients. (external link)
• Dagfinn Lunde Markussen; Paul Christoffer Lindemann; Sondre Serigstad et al. (2025). Microbial profiling of community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease: a comprehensive molecular diagnostics study. (external link)
• Marthe Jøntvedt Jørgensen; Synne Jenum; Kristian Tonby et al. (2020). Monocytic myeloid-derived suppressor cells reflect tuberculosis severity and are influenced by cyclooxygenase-2 inhibitors. (external link)
• Gry Klouman Bekken; Christian Ritz; Sumithra Selvam et al. (2020). Identification of subclinical tuberculosis in household contacts using exposure scores and contact investigations. (external link)
• Erik Christensen; Marthe Jøntvedt Jørgensen; Kristin Grotle Nore et al. (2021). Critical COVID-19 is associated with distinct leukocyte phenotypes and transcriptome patterns. (external link)
• Esteban Garcia-Gallo; Laura Merson; Kalynn Kennon et al. (2022). ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19. (external link)
• Sheryl Ann Abdukahil; Ryuzo Abe; Laurent Abel et al. (2021). Ten months of temporal variation in the clinical journey of hospitalised patients with COVID-19: An observational cohort. (external link)
• Marius Trøseid; Jan Cato Holter; Kristian Holm et al. (2023). Gut microbiota composition during hospitalization is associated with 60-day mortality after severe COVID-19. (external link)
• Rasmus Mortensen; Helena Strand Clemmensen; Joshua S. Woodworth et al. (2019). Cyclooxygenase inhibitors impair CD4 T cell immunity and exacerbate Mycobacterium tuberculosis infection in aerosol-challenged mice. (external link)
• Marianne Bollestad; Nils Grude; Sigrid Solhaug et al. (2018). Clinical and bacteriological efficacy of pivmecillinam treatment for uncomplicated urinary tract infections caused by ESBL-producing Escherichia coli: a prospective, multicentre, observational cohort study.. (external link)
• Dhanasekaran Sivakumaran; Synne Jenum; Ruth Stavrum et al. (2014). Effect of non-tuberculous mycobacteria on host biomarkers potentially relevant for tuberculosis management. (external link)
• Marina Wainstein; Samual MacDonald; Daniel Fryer et al. (2022). Use of an extended KDIGO definition to diagnose acute kidney injury in patients with COVID-19: A multinational study using the ISARIC–WHO clinical characterisation protocol. (external link)
• Camilla Tøndel; Synne Jenum; Kristian Tonby et al. (2026). SARS-CoV-2 T-cell vaccine VB10.2210 induces broad T-cell responses in a phase 1/2 open-label clinical trial. (external link)
• Dhanasekaran Sivakumaran; Synne Jenum; Ruth Stavrum et al. (2013). Identification of biomarkers for Mycobacterium tuberculosis infection and disease in BCG-vaccinated young children in Southern India. (external link)
• Hallvard Berge Pedersen; Robin Sviggum Kaviyani; Else Quist Paulsen et al. (2021). En mann i 70-årene med pleuravæske, knesmerter og dysartri etter åpen hjertekirurgi. (external link)
• Synne Jenum; Kristian Tonby; Corina Silvia Rueegg et al. (2021). A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients. (external link)
• Beathe Kiland Granerud; Mari Kaarbø; Huda Al-Baldawi et al. (2025). Droplet Digital PCR or Real-Time PCR as a Method for Quantifying SARS-CoV-2 RNA in Plasma-Is There a Difference?. (external link)
• Luis Felipe Reyes; Srinivas Murthy; Esteban Garcia-Gallo et al. (2021). Clinical characteristics, risk factors and outcomes in patients with severe COVID-19 registered in the ISARIC WHO clinical characterisation protocol: a prospective, multinational, multicentre, observational study. (external link)
• Synne Jenum; Harleen Grewal; David A. Hokey et al. (2014). The frequencies of IFNγ+IL2+TNFα+ PPD-specific CD4+CD45RO+ T-cells correlate with the magnitude of the QuantiFERON® gold in-tube response in a prospective study of healthy Indian adolescents. (external link)
• Kristin Grotle Nore; Marthe Jøntvedt Jørgensen; Anne Ma Dyrhol-Riise et al. (2020). Elevated Levels of Anti-Inflammatory Eicosanoids and Monocyte Heterogeneity in Mycobacterium tuberculosis Infection and Disease. (external link)
• Dhanasekaran Sivakumaran; Synne Jenum; Ruth Stavrum et al. (2014). TB Trials Study Group: Concordant or discordant results by the tuberculin skin test and the quantiFERON-TB test in children reflect immune biomarker profiles. (external link)
• Synne Jenum; Sumithra Selvam; Diana Mahelai et al. (2014). Influence of age and nutritional status on the performance of the tuberculin skin test and QuantiFERON®-TB Gold In-Tube in young children evaluated for tuberculosis in southern India. (external link)
• Sung-Min Cho; Nicole White; Lavienraj Premraj et al. (2022). Neurological manifestations of COVID-19 in adults and children. (external link)

Popular science article

• Synne Jenum; John Espen Gjøen; Rasmus Bakken et al. (2016). Recent progress in host transcriptome profiling paves the way for a future point-of-care test for pediatric TB. (external link)

Conference lecture

• Anne Ma Dyrhol-Riise; Synne Jenum (2017). Host directed therapy, new treatment options for resistant tuberculosis. (external link)
• Synne Jenum (2019). TBCOX2 study: Host-directed therapy in tuberculosis. (external link)

Letter to the editor

• Kristian Tonby; Rasmus Mortensen; Morten Ruhwald et al. (2019). KLRG1-expressing CD4 T cells are reduced in tuberculosis patients compared to healthy mycobacterium tuberculosis-infected subjects, but increase with treatment. (external link)

Journal corrigendum

• Rasmus Mortensen; Helena Strand Clemmensen; Joshua S. Woodworth et al. (2024). Erratum: Author Correction: Cyclooxygenase inhibitors impair CD4 T cell immunity and exacerbate Mycobacterium tuberculosis infection in aerosol-challenged mice (Communications biology (2019) 2 (288)). (external link)

Conference poster

• Synne Jenum; S. Dhanasekaran; Harleen Grewal et al. (2015). Point-of-care test for pediatric tuberculosis through evaluation of immune biomarkers across the clinical disease spectrum. (external link)
• Marthe Jøntvedt Jørgensen; Synne Jenum; Kristian Tonby et al. (2020). Cyclooxygenase-2 inhibitor as Host-Directed Therapy in Tuberculosis the Effect on Signal Transduction in Monocytes.. (external link)
• Kristin Grotle Nore; Marthe Jøntvedt Jørgensen; Synne Jenum et al. (2019). Eicosanoid balance in tuberculosis - dynamics of lipid mediators in monocytes during infection. (external link)
• Synne Jenum; S Dhanasekaran; Harleen Grewal et al. (2015). Approaching a diagnostic point-of-care test for pediatric tuberculosis through evaluation of immune biomarkers across the clinical disease spectrum.. (external link)
• Rasmus Mortensen; Helene Clemmensen; Joshua S. Woodworth et al. (2018). Treatment with non-steroidal anti-inflammatory drugs (NSAIDs) exacerbates TB infection after aerosol challenge in mice – implications for host-directed therapy. (external link)
• Marthe Jøntvedt Jørgensen; Synne Jenum; Kristian Tonby et al. (2019). Host directed therapy - the in vivo and in vitro effects of Cyclooxygenase-2 inhibitors on myeloid derived suppressor cells in active tuberculosis. (external link)
• Karl Erik Müller; Dagfinn Lunde Markussen; Synne Jenum et al. (2025). Diagnosis and treatment of community acquired pneumonia in hospitalized adult patients in Norway – room for improvement?. (external link)
• S Dhanasekaran; Synne Jenum; Harleen Grewal et al. (2015). Do Non-tuberculous Mycobacteria affect Host Biomarkers Potentially Relevant for Tuberculosis Management?. (external link)
• Marthe Jøntvedt Jørgensen; Synne Jenum; Kristian Tonby et al. (2019). Host directed therapy - the in vivo and in vitro effects of Cyclooxygenase-2 inhibitors on myeloid derived suppressor cells in active tuberculosis. (external link)

See a complete overview of publications in Cristin.